Qualifying Medical Conditions for Medical Use of Marijuana:
SB 778 would amend Florida’s medical marijuana law to add opioid addiction or opioid dependence as a qualifying medical condition for medical use of marijuana. Under current law, a patient must have one of the listed conditions in section 381.986, Florida Statutes, to receive marijuana or a marijuana delivery device; this bill would add a new category for people diagnosed with an addiction to or dependence on an opioid drug.
The bill is narrowly focused and does not change the broader structure of Florida’s medical marijuana program. Its practical effect would be to expand eligibility for medical marijuana certification to a new patient population, potentially allowing physicians to recommend marijuana as part of treatment or symptom management for opioid use disorder. The bill was set to take effect July 1, 2025, but it died in the Senate Health Policy committee.
If enacted, SB 778 would have amended section 381.986, Florida Statutes, by adding opioid addiction or dependence to the list of qualifying medical conditions for medical marijuana. This would have expanded the pool of patients eligible for certification under Florida’s medical marijuana program and could have affected physicians, qualified patients, and medical marijuana treatment centers. Because the bill died in committee, no statutory change resulted.
The available record shows no committee transcript or recorded votes, so there is no detailed public debate to assess. The bill’s introduction suggests a policy interest in expanding treatment options for opioid use disorder, but its failure in the Senate Health Policy committee indicates it did not advance through the legislative process.
The main policy issue is whether opioid addiction or dependence should be treated as a qualifying condition for medical marijuana. Supporters would likely view the bill as a harm-reduction or treatment-expansion measure for people struggling with opioid use disorder, while opponents may have concerns about the clinical appropriateness of marijuana for addiction treatment, regulatory implications, or whether the medical marijuana program should be expanded to include substance use disorders. No specific arguments were recorded in the provided materials.